Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Terminated trial tests drug combo for rare bone marrow cancer

NCT ID NCT06245941

First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tested a combination of two experimental drugs, TQ05105 and TQB3909, in 21 adults with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the drugs could safely shrink an enlarged spleen and improve symptoms. The trial was terminated early, so final results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hennan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • People's Hospital of Tianjin

    Tianjin, Tianjin Municipality, 300122, China

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The Second People's Hospital of Hefei

    Hefei, Anhui, 230012, China

  • Xijing Hospital of the Fourth Military Medical University

    Xi'an, Shaanxi, 710032, China

Conditions

Explore the condition pages connected to this study.